Lincare Carved Out, Gas Margins Revealed, Q4 Guided Soft: A Cleaner Quarter the Stock Had Already Priced

Results vs. Consensus

Q3 2026 Scorecard

Year-over-Year (Q3 2026 vs. Q3 2025)

Sequential (Q3 2026 vs. Q2 2026)

Sequentially the quarter was steady rather than inflecting. Sales rose 1.2%, adjusted operating profit 0.7%, and the margin slipped another 10 bps. The step-up that matters is cash: free cash flow more than doubled from Q2 on the usual second-half timing of tax, interest and incentive payments, and it rose 6% year over year. The step-down that matters is the backlog, which gave back $0.2 billion after Q2's record $1 billion addition.

Assessment: Revenue

Underlying growth of 5% is a point better than Q2, and both of its components contributed. Price added 3%, up from 2% in Q2, with all three gas regions positive: Americas 6%, APAC 3% and EMEA 2%. Volume added 2% for a second straight quarter. The end-market picture was led by electronics (+15%), chemicals and energy (+12%) and manufacturing (+7%), with healthcare (+2%), food and beverage (+3%) and metals and mining (+3%) growing more slowly. Chemicals and energy is the new name on that list: customers on the US Gulf Coast and in China are running harder on raw-material advantages created by the Middle East conflict, and complex refiners need more hydrogen to process heavier, higher-sulfur crude.

Two caveats keep us from calling this an acceleration. First, the CFO said the 2% volume is "roughly split" between backlog start-ups and organic growth, and that most of the organic piece is equipment sales in APAC and EMEA. Base gas volume from existing customers was therefore a small contributor. Second, the reported 9% includes 1 point each of currency, cost pass-through, acquisitions and Engineering timing. Currency is fading and turns into a sequential headwind in Q4, and pass-through carries almost no profit.

Assessment: Margins

Adjusted operating margin of 29.4% sits 30 bps below the prior year and flat once cost pass-through is removed. The line items explain the split. Cost of sales rose 13% and climbed to 52.8% of sales from 50.8%, driven by energy and distribution inflation, cost pass-through, and a heavier mix of the hydrogen (HyCO) business, which carries higher variable costs. SG&A fell 1% in dollars and dropped 90 bps as a share of sales to 9.5%, which is where the productivity work shows up. The company's own pass-through-adjusted bridge says the gas segments added margin (Americas +39 bps, EMEA +6 bps, APAC -13 bps on a weighted basis) and Engineering plus Global Other took away 36 bps. In plain terms, the gas business expanded margin, and the non-gas businesses, Lincare most of all, absorbed the gain.

The full-year picture is now settled. Year-to-date adjusted margin is 29.6% against 29.9% a year ago. To finish 2026 flat with last year's 29.8%, the fourth quarter would need roughly a 30.4% margin on Street sales, about 90 bps above the 29.5% Linde printed in Q4 2025. The May commitment to 40–60 bps of full-year expansion is therefore gone for 2026, and management did not mention it on this call either. The question for 2027 is whether restructuring savings and a contained Lincare let the gas-segment expansion show through at group level.

Assessment: EPS

Adjusted EPS of $4.59 grew 9%, slightly slower than the 10% of Q1 and Q2, and year-to-date adjusted EPS of $13.41 is up 9.4%. Adjusted net income grew 6.8% and the share count did the rest. Two below-the-line items roughly offset: a higher tax rate took off about $0.07 and the equity-income true-up added about $0.04. The CFO quantified the Lincare drag directly: "Year-to-date, we're losing about 2% EPS growth from Lincare." That framing implies the rest of Linde is compounding at roughly 11%, the upper half of the 8–12% algorithm. GAAP EPS of $3.66 fell 11% because of the $425M charge, worth $0.57 per share after tax. The trajectory problem is Q4: the $4.45 guide midpoint implies 6% growth, the slowest of the year.

Segment Performance

Linde recast its segments this quarter. US homecare (Lincare) moved from the Americas into Other, and all prior periods were restated. Every comparison below uses the recast figures, so the Americas margins will not match those printed in our Q2 note. Segment operating profit is the adjusted figure; reported operating profit of $2,150M is after $425M of restructuring charges and $188M of Linde AG purchase-accounting impacts.

Sales bridge by segment (Q3 2026 vs. Q3 2025)

Weighted margin bridge, excluding cost pass-through (Q3 2026 vs. Q3 2025)

Americas

On the recast basis the Americas is now a pure industrial gases business, and it had the best quarter of any segment. Sales rose 11% to $3,601M with 9% underlying growth (6% price, 3% volume), operating profit rose 12% to $1,263M, and margin expanded 50 bps year over year and 30 bps sequentially to 35.1%. Volume came from electronics, chemicals and energy, and metals and mining. US packaged gas grew at a low-teens rate on construction and data-center activity, and merchant and on-site volumes were strongest in the US.

The 6% price needs a footnote. Management said close to 2 points of it recovered energy and distribution costs from the current and prior quarters, and that the recovery dilutes margin even as it adds profit dollars.

"So I would just say it's been spread over a couple of quarters for the most part, within the quarter itself, it would have still been net dilutive to the 35% margins that we printed just given the recovery portion." — Matt White, CFO

The removal of Lincare also flatters the optics. Lincare took almost $2.3 billion of annualized sales out of the segment, so the same pricing dollars are now a larger percentage of a smaller base.

Assessment: This is the segment the thesis has always rested on, and for the first time in our coverage it is visible without the homecare drag. A 35% margin expanding while absorbing a margin-dilutive cost recovery is a strong result. Model Q4 price lower, toward the ~4% underlying run rate, because the catch-up portion is expected to ease.

APAC

APAC grew sales 12% to $1,950M with 8% underlying: 5% volume and equipment, 3% price. Operating profit rose 9% to $534M, but margin fell 70 bps to 27.4%, or 40 bps excluding pass-through, and slipped 100 bps sequentially from 28.4%. The company named two causes: sale of equipment to electronics customers and helium dislocation costs. Roughly half of APAC price came from helium, which raises cost almost as fast as it raises price. China grew on electronics while steel contracted under a production curtailment and chemicals were flat.

"So steel is down, chemicals flat. The star of the show really has been electronics in China." — Sanjiv Lamba, CEO

Assessment: In Q2 we told readers to stop modeling the equipment dilution as temporary, and Q3 confirms it. APAC is now a volume engine with a structurally lower margin while the electronics build-out continues. That trade is acceptable because equipment sales seed long-term gas contracts, but the 29% APAC margin from 2025 is not coming back soon.

EMEA

EMEA sales rose 7% to $2,327M on 3% pass-through, 2% price, 1% volume and 1% acquisitions, with no currency effect. Operating profit rose 5% to $817M, and the 35.1% margin was 80 bps lower on a reported basis but flat excluding pass-through. Volume came from healthcare and food and beverage, the defensive end markets. The CEO was explicit that the 1% volume figure is flattered by equipment sales and that underlying volume is flat, but he framed flat as progress against the declines of a year ago.

"But a flat number today for Europe actually is looking better than the minus 2, minus 3 that we've seen if you go back 12, 18 months ago." — Sanjiv Lamba, CEO

Assessment: EMEA is a stable, high-margin franchise with no growth and, by the CEO's account, no catalyst. Energy prices are now the variable to watch. Price recovery in merchant and packaged gases runs three to six months behind cost, so a winter power spike would show up as a margin lag before it shows up as price.

Engineering

Engineering sales rose 12% to $582M on project timing, and operating profit rose 6% to $107M at an 18.4% margin, down from 19.5% a year ago but up from 16.0% in Q2. Order intake was $499M, well below Q2's $871M but above $269M a year ago, and the third-party sale-of-plant backlog stands at $2,941M. Management expects that backlog, which now includes a space component, to grow through 2027.

"So I expect the trend line for sale of plant backlog will remain along the lines we have at this point in time, growing over the course of next year." — Sanjiv Lamba, CEO

Assessment: Engineering remains a timing business. The intake drop from Q2 is not alarming against a lumpy history, but it is one more input that leaned negative on the backlog side this quarter.

Other (now including US homecare)

Other now holds corporate costs, Linde Advanced Material Technologies, global helium wholesale and, since this quarter, Lincare. Sales rose 2% to $944M and operating profit fell $20M to $42M, which the 10-Q attributes primarily to declines in US homecare, partly offset by growth in the materials business. The $29M sequential decline from $71M was mostly a prior-quarter corporate cost benefit that did not repeat.

The recast lets us size Lincare for the first time by comparing the restated Q2 figures with those originally reported. Q2 2026 Americas sales fell from $4,083M as reported to $3,504M as recast, and operating profit fell from $1,272M to $1,219M. That puts Lincare at about $579M of quarterly sales and $53M of operating profit, a 9.2% margin. The same calculation for Q2 2025 gives $588M and $93M, a 15.8% margin. In other words, Lincare's quarterly profit fell by about $40M in a year on almost unchanged sales, and it earns less than a third of the margin of the gas business it was reported inside.

"As we continue to trim the Lincare portfolio, I expect the sales trends to lag market average, but I fully expect to see improvements in both the quality and profitability of the remaining businesses." — Sanjiv Lamba, CEO

Assessment: Moving Lincare into Other is a disclosure gain and an analytical gift. It separates a roughly $2.3 billion low-margin health-care distribution business from a 35%-margin gases franchise, and it confirms that the deterioration is concentrated rather than spreading. It does not fix anything, and the segment that now holds Lincare is also where corporate cost noise lands, so quarterly Lincare trends will stay hard to read.

End-market trends (excluding currency, pass-through, M&A and Engineering)

Key KPIs

Key Topics & Management Commentary

Overall Management Tone: Contrite at the open and businesslike after it. Management began by conceding that last quarter's results fell short of owners' expectations, then spent the call on actions (a sized charge, a segment change, pricing and productivity) rather than on promises, and the CFO framed the Q4 guide as deliberately cautious, naming the cushion rather than leaving the Street to anchor at the top of the range as it did in July. Confidence was high on electronics, pricing and the gas franchise, flatly negative on Europe, and noticeably more hedged on Lincare's exit than in July.

1. "Received Loud and Clear": Management Owns the Q2 Miss

Last quarter the CEO named the margin problem in the opening minute. This quarter he opened by naming the market's reaction to it, which is rarer. The first words of the prepared remarks tied the quarter's actions directly to shareholder dissatisfaction with July.

"Three months ago, we delivered financial results that were not up to the expectation of our owners. That message was received loud and clear by the Linde organization. And so we have and will continue to take actions that increase shareholder value." — Sanjiv Lamba, CEO

He closed the prepared remarks in the same register, framing the restructuring and the Lincare changes as an expression of the operating model rather than a reaction to it.

"Linde's operating model is built on discipline, accountability and continuous improvement. When performance falls short, we act. When conditions change, we adapt." — Sanjiv Lamba, CEO

Assessment: The tone is right and so is the sequencing: the charge, the recast and the reporting-line change all landed in the quarter immediately after the sell-off. We give management credit for responding quickly. Accountability language is cheap, though, and the measure is whether group margin expands year over year by the first half of 2027.

2. The $425 Million Charge: What It Buys and When

In July the CFO previewed cost actions without a size. This quarter they arrived: $425M in total, of which $200M is global severance, $42M is other cost reduction, and $183M is non-cash charges primarily related to US homecare. Cash outflow for restructuring in the quarter was only $36M, so most of the severance cash is still to come.

"During the third quarter, we recorded a $425 million restructuring charge to better align our cost base and portfolio with market conditions. Roughly half relates to severance, particularly in lower growth regions. The balance relates primarily to portfolio and asset actions, mostly in the U.S. home care business or Lincare." — Sanjiv Lamba, CEO

Management gave a payback period rather than a savings figure, near the two-year end of its usual one-to-two-year range, with savings starting in Q4 and reaching full run rate in the second half of 2027. Asked whether the savings simply replace the normal productivity embedded in the earnings algorithm, the CFO said they are additive.

"It will be on top, right? The way we always view it is the productivity is an ongoing embedded in the culture. That is an expectation, and that is every day. These restructurings are more episodic onetime, and they're more top-down approaches that are incremental." — Matt White, CFO

Assessment: A two-year cash payback on $200M of severance implies roughly $100M of annual savings at full run rate. That is our inference, not a company number, and it is worth about $0.16 per share after tax, or just under 1% of FY26 EPS. That is helpful but modest. The larger value is that the savings are explicitly incremental to the algorithm, which gives 2027 a self-help tailwind that 2026 did not have.

3. Lincare Moves to Other: Transparency, Not Yet a Transaction

The CEO moved Lincare's reporting line to the CFO, which triggered the segment change. Management presented the move as a transparency measure for the gas business while the restructuring and the review of strategic alternatives continue.

"Effective this quarter, I realigned this business to report directly to Matt, which, among other reasons, has prompted us to modify the segment reporting by moving it into the Global Other segment. This will provide investors with greater insight into the underlying performance of our regional Gases businesses, while we continue to restructure Lincare and evaluate strategic alternatives." — Sanjiv Lamba, CEO

The CFO offered a precedent. A previous non-core business sat in EMEA, moved to Other under new executive oversight, and was eventually sold.

"We changed the oversight of it. We changed how we managed and reviewed that internally. It moved to the other segment. That business ended up a sale. We'll see what happens in this case." — Matt White, CFO

Against that precedent, the same answer set much lower expectations for a near-term deal than July's "in part and as a whole" language did, a point we take up in the Q&A section.

Assessment: The precedent is encouraging and the timeline is not. Management is now saying, in effect, fix it first and then see whether a buyer exists in a weak health-care services market. That is a sensible order of operations and a slower path than the market hoped for in July. We keep the Lincare risk on the scorecard and raise its status because the drag is confirmed and the exit is less certain.

4. The Gas Business, Seen Without Lincare

The most important analytical change this quarter is not a number Linde reported. It is that the reported numbers can finally be read cleanly. The CFO said gas-segment margin gains were offset by Engineering and Global Other, and the CEO put the same point in one line.

"However, operating margin, excluding cost pass-through, was essentially flat, reflecting continued headwinds from non-gas segments." — Sanjiv Lamba, CEO

"Operating margin of 29.4% fell 30 basis points from prior year, but was flat excluding cost pass-through, which is highlighted in the table to the right. Margin increases of the combined gas segments were offset by declines in Engineering and Global Other." — Matt White, CFO

The recast numbers support this. Combined Americas, EMEA and APAC sales rose 9.8% and operating profit 9.1%. The reported gas-segment margin was 20 bps lower at 33.2% because of pass-through in EMEA, but it was higher on the company's pass-through-adjusted bridge. Every gas segment grew operating profit: Americas +12%, APAC +9%, EMEA +5%.

Assessment: This is the strongest evidence yet that the July margin problem is a portfolio problem rather than a franchise problem. It strengthens Bull 1 (pricing) and supports Bull 3 (self-help) in the businesses that matter for the multiple. It does not satisfy the trigger we set, which is group margin expansion. We are not re-cutting that trigger to a gas-only measure, because Lincare is still inside the group and still inside EPS.

5. Price at 3%, With a Catch-Up Inside It

Group price of 3% was up from 2% in Q2. The CFO broke it into ongoing price actions and a recovery of earlier cost inflation concentrated in North America, and he expects the recovery portion to ease in Q4.

"Prices increased 3% in the quarter. While the majority came from ongoing price actions, a portion relates to prior and current period inflation cost recovery in the Americas. An acceleration of energy and distribution cost pressures in North America warranted incremental recovery. While we don't anticipate these costs to sustain into the fourth quarter, the team is prepared for additional measures, if necessary." — Matt White, CFO

Management also signaled that inflation is building in places where it has been absent, which would extend pricing power beyond the Americas.

"So including China, which is a lower inflation economy, I think for the first time after a number of quarters, we've seen positive inflation in China." — Sanjiv Lamba, CEO

Assessment: In Q2 we noted that price plus productivity failed to offset cost inflation for the first time. In Q3 price and productivity outran cost inflation in every gas segment, which is why we restore confidence in Bull 1. The underlying run rate is about 4% in the Americas and 3% globally, so the Q3 headline overstates the durable rate by perhaps a point in the Americas. A building inflation backdrop is good for this business model, with a lag.

6. Volume: Half From the Backlog, the Rest Mostly Equipment

The 2% volume figure matches Q2, but its composition matters more than its size.

"Volume of 2% is roughly split between project backlog contribution and organic growth, although most of the organic growth relates to equipment sales in APAC and EMEA." — Matt White, CFO

Regionally, the US was strongest: Gulf Coast energy and chemicals, metals production, packaged gas tied to construction and data centers, and space propellant. Europe was flat excluding equipment. In China, export strength carried the economy while domestic demand stayed weak.

"Domestic demand continues to not manifest itself at all. That remains my concern, to be honest. Sustained improvements in China require the domestic consumption to pick up alongside some level of export growth." — Sanjiv Lamba, CEO

Assessment: Bear 2 (absent base volume) stays contained, but its quality is lower than the headline suggests. Contracted start-ups and equipment sales are good volume, yet organic gas demand from the installed base is growing only in the US. Linde is growing through its backlog and its pricing, not through a broad industrial recovery, which is why management again assumes no economic improvement in its guide.

7. Electronics: +15% and $2 Billion Under Construction

Electronics remains the engine. Growth of 15% came mainly from organic demand in APAC and the US, and excludes the 50%-owned Taiwan joint venture, which management says is growing at a similar rate.

"Electronics leads with 15% growth, primarily driven by the organic growth across APAC and the U.S. These figures exclude our 50% Taiwanese joint venture, which is growing at similar rates. We also have approximately $2 billion of electronics projects under construction in the U.S., Korea and China, providing a strong foundation for continued double-digit growth." — Sanjiv Lamba, CEO

Management also drew a line on project selection, favoring logic customers and long contracts and staying selective on memory projects because of their shorter cycles.

Assessment: Growth eased from 18% in Q2 to 15%, but on a larger base and with $2 billion of projects still to start. The memory comment is good capital discipline, and it is also a reason not to expect backlog additions at the pace of a memory-driven build cycle. Electronics is the most reliable piece of the growth case.

8. The Backlog Dips to $7.9 Billion, and the "8 Handle" Softens

In July management said the sale-of-gas backlog would finish 2026 with an "8 handle" even after more than $1 billion of second-half start-ups. Three months later the backlog is $7.9 billion with no new award announced, and the year-end language is less firm.

"My expectation remains we will continue to start up for the rest of this quarter, a number of projects that might lead up to around $1 billion, as we previously mentioned. And depending on customer timings, we expect still to be able to get pretty close to that $8 billion number. So the target internally remains at 8 handle. Sometimes that's dependent on customers' final decision, but feel pretty confident we're going to be in that vicinity." — Sanjiv Lamba, CEO

The arithmetic is demanding. About $1 billion of start-ups leaves the backlog in Q4, so holding near $8 billion needs roughly $1 billion of new signings within the quarter.

Assessment: A $0.2 billion dip after a $1 billion record quarter is not a trend, and start-ups leaving the backlog are revenue arriving, which is the point. But "pretty close" and "in that vicinity" are softer than July's commitment, and the "8 handle" is now explicitly dependent on customer decisions. Bull 2 stays on track with a watch flag on Q4 signings.

9. The Q4 Guide: Three Points of Sequential Decline, Explained

The Q4 guide of $4.40–$4.50 implies about a 3% sequential decline from $4.59 at the midpoint. The CFO broke that into three roughly equal pieces: a 1% currency headwind as the dollar strengthens, 1% from the non-recurring equity-income true-up, and 1% of seasonality and caution. He also said the guide assumes no profit improvement at Lincare.

"Despite the recent actions, we are not yet embedding any meaningful change to Q4 profit. While I fully expect future improvement, we're taking a more cautious view for the near term." — Matt White, CFO

"But our goal is to do better than this range, and our goal is to work to get above it. But that's where we are right now." — Matt White, CFO

Assessment: This is the conservatism the market punished in July, applied more transparently. Two of the three points (FX and the true-up) are mechanical and credible. The third is a deliberate cushion. Linde has beaten its own guide midpoint in each quarter of 2026, so the base case should be a Q4 near the top of the range, around $4.50, which would put FY26 near $17.91.

10. Woodside: Nitrogen On, Hydrogen in H1 2027, Owner Under Review

After a quarter of silence in July, the large US Gulf Coast ammonia project was addressed directly. The air-separation unit started nitrogen supply in Q3. The two autothermal reformer trains start in the first half of 2027, earnings contribution arrives in the second half, and the plant reaches full utilization around 2028.

"Now the ATRs, which is our on-site supply for hydrogen will get started up. There are 2 trains for the ATR. So there is always a staggered start-up. I expect that to be completed in the first half." — Sanjiv Lamba, CEO

"So once we start up, then we will start going into that ramp process, which would mean there be a staggered capacity utilization of our plants until we get to that 100%, which I expect probably to be sometime in 2028." — Sanjiv Lamba, CEO

Two complications emerged. The customer, which acquired the asset from its original owner, has put it under a strategic review. And until the reformers start, Linde is supplying hydrogen from its own pipeline network, which costs it molecules it could otherwise sell to Gulf Coast refiners at today's elevated value.

Assessment: The timeline held and the nitrogen phase is live, which clears one of July's open questions. The ramp to 2028 means this project's full earnings land later than a simple start-up date implies. Linde's contract protection, and the CEO's point that the complex is a high-quality asset whoever owns it, make the ownership review a watch item rather than a risk.

11. Helium: Price Up Everywhere, Margin Still Flat

Helium prices rose in every region, and Linde signed new long-term contracts with customers drawn to its supply resilience. But pricing has been set to recover dislocation costs rather than to maximize margin, so the economics are close to neutral.

"So we are seeing that rounded up in pricing. But of course, that is also rounded up in the cost structure. Therefore, the margin improvements don't quite show through on the helium and affect us more broadly." — Sanjiv Lamba, CEO

On 2027, the CEO expects Qatar to recover to about 75% of production, but said exports remain constrained by shipping routes and a shortage of tanks, and declined to forecast normalization.

"And if you could give me a date by when the Strait of Hormuz issues would get resolved, I would tell you exactly what the helium would look like. But neither of us are in a position to do that today." — Sanjiv Lamba, CEO

Assessment: Helium has settled where we put it in July: a modest positive in dollars, roughly neutral in margin, and impossible to time. The new long-term contracts are the durable gain, because they lock in volume for the post-normalization market, which management expects to be long on supply.

12. Cash Flow Recovers, Buybacks Still Slower

Operating cash flow rose 8% to $3,169M, in line with EBITDA, and free cash flow rose 6% to $1,777M after $1,392M of capex. Base capex was flat; project capex rose 18% as the backlog is built. Year-to-date free cash flow of $3,508M is flat with 2025, and net share purchases of $2.6 billion are 18% lower. Debt fell by $1.1 billion in the quarter.

"We've deployed over $9 billion of capital year-to-date, with roughly half invested into the business and the remainder distributed back to shareholders. We've maintained this approach through good times and bad, and the rising interest rate environment reinforces something we have known for a long time." — Matt White, CFO

Assessment: The Q2 cash dip was timing, as management said, and the year-to-date picture is now flat rather than shrinking. The capital mix has still shifted toward project investment and away from buybacks, and return on capital has eased to 23.5% from 24.6% a year ago. That is the expected cost of a growth-capex phase, and it is why we no longer value Linde on a pure cash-return multiple.

Guidance & Outlook

The full-year range is the year-to-date $13.41 plus the Q4 range, nothing more. The midpoint moved $0.07 to $17.87, slightly less than the $0.09 by which Q3 beat its own guide midpoint, because the implied Q4 midpoint fell $0.02 to $4.45. Management attributed the Q4 softness to currency, the non-recurring equity-income true-up and caution on both the economy and Lincare. It deferred everything about 2027 to February, beyond a conditional statement that offsetting Lincare would return the group to double-digit EPS growth.

Implied Q4 ramp: $4.45 at the midpoint is 6% above Q4 2025's $4.20 and 3% below Q3's $4.59. Q4 2025 adjusted margin was 29.5%, the softest comparison of the year, so Q4 2026 is the first realistic chance for year-over-year group margin expansion. The guide does not assume it.

Street at: Pre-print consensus sat near $17.89 for the year and in a $4.46–$4.51 range for Q4. The new full-year midpoint of $17.87 is effectively at the Street, a marked change from July, when the midpoint sat $0.09 below a Street parked at the top of the range. Q4 is guided a cent to six cents below consensus, which the market treated as conservative rather than as a warning.

Guidance style: Conservative, and this time explicitly so. The CFO named the cushion, stated a goal of beating the range, and declined to bank either the restructuring savings or any Lincare improvement. After beating its own midpoint in each quarter of 2026, Linde has earned the benefit of the doubt on Q4. The open question is the February 2027 guide, where the same conservatism would again place the initial range at or below the bottom of the 8–12% algorithm.

Analyst Q&A Highlights

Why unit costs rose about 10% while volume and acquisitions rose 3%

The first cost question of the call asked management to reconcile a 13% rise in cost of sales with low single-digit volume and acquisition growth. The answer itemized currency, pass-through and the hydrogen business, and then made an important point about how the recast changes the optics of Americas pricing.

Q: "If you look at your COGS line in Q3, year-over-year, you're up 13% and your acquisitions and volume are up 3%. So if you just subtract that, kind of a cheap metric would say that your per unit COGS is up about 10% per unit. Can you just walk through what that is?"
— Duffy Fischer, Goldman Sachs

A: "In addition, as you saw, the energy market did quite strong, and a lot of that's on the back of HyCO, our hydrogen business, which tends to have, as you know, a higher variable cost just given the inputs for that business... I would say, secondly, which is just more optics is as we move Lincare out of the Americas segment, while this recovery had always happened, it's going to look a little more pronounced now because you're taking Lincare out of the denominator of that calculation."
— Matt White, CFO

Assessment: A complete answer, and an honest one about the denominator effect. Cost inflation is real and concentrated in energy, distribution and hydrogen inputs, and the price recovery is real too. The recast will make Americas pricing look stronger in percentage terms from here, so readers should compare like with like.

What the severance charge saves, and when

A question on the non-Lincare portion of the charge asked how the savings compare with Linde's normal annual efficiency gains. Management answered with a payback period and a timeline rather than a dollar figure.

Q: "Regarding the charge that you took in terms of the severance side, so the non-Lincare portion of the restructuring and efficiency work that you're doing, I guess, can you help us to think about how that will play out going into 2027 in terms of the savings and the improved efficiency versus your kind of normal cadence that you call out most of the time in terms of efficiency improvements that we kind of know as a steady state?"
— John McNulty, BMO Capital Markets

A: "So as you may recall, the paybacks on a cash basis, undiscounted tend to be in the 1- to 2-year range... So I would say for this particular charge, it's probably closer to the higher 2-year end, but that will start taking effect here in the fourth quarter. But really, we'd expect to see the full benefits in the second half of next year on a full run rate basis."
— Matt White, CFO

Assessment: The payback framing is consistent with past programs, which have delivered. Combined with a later answer that the savings are additive to normal productivity, this gives 2027 a modest, identifiable self-help tailwind. A dollar target would have been more useful, and its absence is one of the omissions we list below.

Why Q4 growth decelerates from 9% to about 6%

The most direct guidance question asked what drives the slowdown from Q3 to Q4 and what it implies for 2027. Management declined the 2027 part and decomposed the sequential decline into three pieces.

Q: "I wanted to ask kind of simply here, just in terms of your EPS guidance versus what you just delivered, 9% growth versus 7% growth. What are the factors that drive the deceleration in fourth quarter versus 3Q? And what should we be inferring from fourth quarter as we look forward into 2027?"
— Josh Spector, UBS

A: "So for 2027, we'll give that in February... It's about a 3% decline. 1% is FX, as we mentioned... And a lot of that was a customer true-up on a contract we were paid for that was resolved... As I mentioned, we're taking a pretty guarded view on the impact of some of the actions we're taking with both the non-gas business as well as our view on the economy right now."
— Matt White, CFO

Assessment: The decomposition is credible and it identifies the equity-income true-up as non-recurring, which tells us the Q3 beat was about $0.04 smaller than it looked. The remaining point of caution is the only discretionary element, and it is where Linde's beat pattern usually comes from.

Why Lincare moved, and whether it will be sold

A direct question on the logic of the segment change and the possibility of a sale drew the call's most important hedge. Management called the move an accounting consequence of changed oversight, and then lowered expectations for a transaction.

Q: "I was hoping you could elaborate a little bit more on any other reasons for logic of moving Lincare to the other segment, whether you're considering selling that business? And just any sort of update on the mitigation actions you plan to take? When can we expect a meaningful change in profit levels there?"
— Patrick Cunningham, Citi

A: "But that being said, we absolutely, and we've said we will continue to evaluate strategic options, but we can't assure there will be a strategic option to be had. And so we have to improve this business. We have to run it better while running it safely and compliantly... Hopefully, the health care sector improves. Right now, it's not doing as well, I'll say, as a sector."
— Matt White, CFO

Assessment: The question about when profit improves went unanswered, and the answer on a sale walked back July's "in part and as a whole" language toward a fix-first plan that depends on the health-care sector recovering. Read together with the Q4 guide's assumption of no Lincare improvement, this pushes any resolution into 2027 at the earliest. It is the main reason the Lincare risk rises on our scorecard.

How much of the Americas' 6% price is durable

A question comparing regional pricing produced the clearest split between run-rate pricing and one-time recovery, plus a useful disclosure on APAC.

Q: "I was wondering if you could compare and contrast your price experience in the Americas versus your other major regions. I'm looking at plus 6% in the Americas and maybe half that in Asia and 1/3 of that in Europe."
— Kevin McCarthy, Vertical Research Partners

A: "When you look at the 6%, I would say probably close to 2% associated with some of this recovery we talked about. So underlying run rate here in the 4% range... And when you move to APAC right now, probably half of that pricing is helium"
— Matt White, CFO

Assessment: The Americas run rate of about 4% is still strong, and it is above what the business needs to compound. APAC is weaker than its 3% headline, because half of it is helium that carries matching cost. Pricing power is intact and broadening, but Q3's headline is the high-water mark for now.

Whether electronics outgrowth is sustainable, and where new projects come from

A question on electronics growing well ahead of its end market drew a confident answer on the next few quarters and an explicit statement of project discipline.

Q: "In Electronics, you've been growing mid- to high teens this year versus what I think MSI growth at 8% to 10%. Is this a sustainable level of outgrowth for the next few quarters? And separately, how do you feel about prospects of new additions to backlog in electronics?"
— Aleksey Yefremov, Barclays

A: "So the growth that we saw in the quarter is really largely driven around organic growth in electronics, and I feel pretty good about the trend that we see at least for the next few quarters, looking out in terms of how that end market is going to perform for us... I will say, though, that we are, as you know, very disciplined around capital allocation. And one of the things that we are playing into that has been our focus on logic."
— Sanjiv Lamba, CEO

Assessment: Confident on demand and deliberate on selection. The logic-first stance protects returns but also explains why backlog additions may come in steps rather than continuously. The commitment to double-digit electronics growth is backed by $2 billion of projects under construction.

Whether Europe has found a floor

A question on whether European trade protection could revive industrial demand produced the bluntest answer of the call.

Q: "Sanjiv, I have a feeling what your answer will be, but are you getting any more optimistic that the Europeans are taking a bit more defensive view on industry there now with like steel antidumping and the auto import cap?"
— Matthew DeYoe, Bank of America

A: "So there seems to be a degree of stability, but there is absolutely no catalyst, and I have absolutely no reason for any confidence that European market will pick up and give us any growth in the near-term... And I do not see the pragmatism that is needed across that whole European Union and the European community to take decisions that could get back industrial activity to a level where actually we start seeing some positive movement."
— Sanjiv Lamba, CEO

Assessment: Stability without a catalyst is the right description. Europe's contribution to the investment case is margin defense and cash generation, not growth, and management's candor removes any temptation to model a recovery.

How large the Lincare drag really is

An attempt to reconcile the stated 2% EPS growth drag with first-half Lincare profit declines produced a range and a characteristic hedge.

Q: "And then for Matt, at least by my calculation, the decrease in Lincare EBIT in the first half was $66 million... So are you rounding up? Is the number a little less than that?"
— Jeff Zekauskas, JPMorgan

A: "But it is about 1.5% to 2% on the year-to-date and especially when we kind of look out on holding flat what the Q4 would be. And part of that also is a function of how last year the performance was when you think about the baseline... But I would say it's a very strong 1 to a weak 2 is what we've seen on when we project out on the year just based on the numbers."
— Matt White, CFO

Assessment: "A very strong 1 to a weak 2" points of EPS growth is consistent with our recast-derived estimate of about $40M of lost quarterly operating profit. It also bounds the problem: Lincare is costing Linde roughly two points of growth, not threatening the algorithm.

What They're NOT Saying

1. No Lincare line in the filing. The recast moves homecare into Other alongside corporate costs, the advanced materials business and helium wholesale, and the 10-Q discloses no separate sales or operating profit for it. Q2 can be derived from the restated figures, but Q3 cannot. Investors are asked to judge a restructuring with no clean way to track it quarter to quarter.
2. No savings figure for the $425M program. The release, 10-Q and call give a payback period and a timeline, not a dollar target. Our ~$100M estimate is an inference from a two-year payback on $200M of severance.
3. No detail on the $183M non-cash charge. The 10-Q describes "various non-cash charges totaling $183 million primarily related to the U.S. homecare business" without naming the assets written down or what remains on the balance sheet. That matters for any future sale price.
4. The 40–60 bps margin commitment is gone without a word. For a second straight call the May commitment was not mentioned, and year-to-date margin of 29.6% against 29.9% means FY26 will very likely show a decline. No replacement margin target was offered for 2027.
5. No new backlog award. The sale-of-gas backlog fell $0.2 billion, no new project was named, and the year-end "8 handle" now depends on "customers' final decision."
6. The space opportunity went unsized. Space appeared only as propellant demand and a component of the sale-of-plant backlog, alongside softer rare-gas sales for satellite propulsion. The $1 billion-plus by 2030 frame from prior calls was not repeated.
7. Helium is still unquantified. For a third straight quarter management described helium as positive in pricing and neutral in margin without a dollar figure, which keeps the most discussed swing factor out of the model.
8. No 2027 frame beyond a conditional. Everything about 2027 was deferred to February, except the statement that offsetting Lincare "will support the return to double-digit EPS growth," which is a conditional rather than a target.

Market Reaction

• Pre-print setup: LIN closed at $508.16 on October 28, entering the October 29 before-the-open print up 19.2% year to date against 13.1% for the S&P 500, up 17.6% over the trailing twelve months and up 7.3% over the trailing 30 days. The stock had recovered 6.2% from the $478.38 close after the Q2 print and sat 7.0% below its $546.64 52-week closing high.
• Reaction session (October 29): Shares opened 0.2% higher at $509.39, traded a $498.35 to $513.26 range, and closed at $503.15, down 1.0% or $5.01. Volume of 2.8 million shares was 1.4 times the 2.1 million 30-day average. The S&P 500 fell 0.3% the same session.
• Next session (October 30): LIN rose 2.2% to $514.24 on 3.1 million shares, about 1.5 times average, while the S&P 500 fell 1.8%. Over the two sessions LIN gained 1.2% against a 2.1% decline in the index.
• Peers: Air Products rose 1.5% on each of the two days (+3.0% combined) and Air Liquide rose 1.8% and 2.0% (+3.8% combined), so industrial gases traded as a defensive group into a falling market, and LIN lagged its two largest peers over the window.

The first-day move was a small version of July's. The headline beat was clear before the open, and the stock opened higher. It then traded down as much as 1.9% during the session as the call confirmed a Q4 guide below the Street, no Lincare improvement in the outlook, a lower backlog and a group margin still down year over year. The close at -1.0% says the market took the cautious Q4 framing at face value for one session.

The second day reversed it, and the reversal is more informative. Sell-side desks lifted price targets broadly after the call, and the stock rose 2.2% on heavier volume in a session when the S&P 500 fell 1.8%. The likeliest reading is that investors digested the recast overnight: once Lincare is separated, the gas business is expanding margin, pricing is strong, and the problem is contained in a business management is visibly working on. A defensive rotation into the gas group helped. Both large peers rose on both days, which suggests part of the move was sector positioning rather than stock-specific news.

We read the two-day outcome as fair. July's 5.9% drop priced a franchise whose margin was deteriorating. This quarter showed the franchise's margin is not deteriorating, so a recovery was warranted. The stock has now recovered 7.5% from the July close, more than the change in fundamentals alone: the FY26 midpoint rose only 0.4% over the same period. Nearly all of the rebound has come from the multiple, which is back to where it was before the July sell-off.

Street Perspective

Debate: Does the recast reveal a better business, or just relabel a problem?

Bull view: The bull camp argues the recast is the most useful disclosure Linde has made in two years. A pure-play Americas gases business at a 35% margin, expanding while absorbing cost recovery, is the franchise the premium multiple was always for, and the drag is now isolated in a $2.3 billion non-core business on a clear path to restructuring or sale.

Bear view: Skeptics note that the group still earned a lower margin than a year ago, that EPS is reported at group level, and that relabeling a business does not change its contribution. Lincare is still inside earnings, its quarterly profit is now harder to track, and management walked back the sale language in the same call.

Our take: Both are right about different things. The recast is real information: it confirms the margin problem is concentrated, which reduces the risk to the franchise. It is not a margin recovery, and we will not treat it as one until group margin expands. That is why our trigger stays at group level.

Debate: Was Q3 pricing a new run rate or a one-quarter catch-up?

Bull view: Inflation is building across regions, including the first positive Chinese inflation in several quarters, and Linde's contracts let it recover cost with a lag. A 3% group price with a 4% underlying run rate in the Americas is ahead of what the algorithm needs, and more recovery is likely if energy costs rise into winter.

Bear view: The Q3 number included close to 2 points of Americas catch-up that management expects to ease, half of APAC price is helium that brings its own costs, and the recovery itself dilutes margin. Pricing that recovers costs at zero margin flatters revenue more than profit.

Our take: Closer to the bull side. The underlying pricing rate is healthy and broadening, and a lagged recovery model is a strength in an inflationary period. Model Q4 group price nearer 2–3% and treat Q3 as the year's high point, not the new base.

Debate: Will Lincare be sold, or fixed and kept?

Bull view: The precedent management cited (a non-core business moved to Other under new oversight, then sold) is exactly what is happening now, and a $183M write-down plus a restructuring makes the business easier to sell. Removing a roughly 9%-margin business would lift group margin and remove a two-point growth drag in one step.

Bear view: Management said it cannot assure a strategic option exists, the health-care services market is weak, and the Q4 guide assumes no improvement. A fix-first plan in a sector with reimbursement pressure could take years, and in the meantime the drag continues.

Our take: The bear view has the timing right. We expect Lincare to stay inside Linde through at least mid-2027. The upside from a sale is real but undated, and the stock should not pay for it in advance.

Debate: Has the stock already paid for the recovery?

Bull view: On FY27 consensus the stock trades near 26x, below its historical premium, for a business with double-digit electronics growth, incremental restructuring savings in 2027, a Woodside contribution starting in the second half, and a long record of dividend growth. If Lincare is offset, management says EPS growth returns to double digits.

Bear view: On the same FY26 basis we used in July, the multiple has re-expanded from 26.9x to 28.8x in three months without a change in guidance of any size. Group margin is still falling, Q4 growth slows to 6%, and the February guide is likely to start conservatively again.

Our take: The bears have it on valuation. Comparing like with like, the July discount is gone, and the stock now sits where we called it full in May. The business is in better shape than in July, but the price already reflects that.

Model Update Needed

Valuation impact: At the $514.24 close on October 30, LIN trades at 28.8x the $17.87 FY26 midpoint and 26.5x our $19.40 FY27 estimate, with a 1.2% dividend yield on the $1.60 quarterly rate. On the same FY26 basis, the July close of $478.38 was 26.9x and the May reaction close was 28.6x, which we described then as full. We raise fair value to about $510 from $500, which is 28.5x the FY26 midpoint and 26.3x our FY27 estimate. The increase reflects the higher FY26 midpoint, the incremental 2027 savings and the clearer read on gas-segment margins, partly offset by the softer Q4 and the lower backlog. That fair value sits about 1% below the current price and 1.4% above the reaction-day close, so the stock is at fair value rather than at a discount.

Q2 Commitments Revisited

Thesis Scorecard Post-Earnings

Overall: The thesis is clearer than it was in July, and modestly stronger on operations. The recast confirmed that the margin damage is concentrated in a non-core business, pricing outran inflation again, a sized restructuring adds a 2027 tailwind, and the guide is no longer below the Street. Against that, the backlog stepped back, the Lincare exit became less certain, and group margin has still not expanded. The biggest change is not in the business. It is in the price: the de-rating that made July's setup the most attractive of our coverage has fully reversed.

Action: Maintain Hold; fair value raised to about $510 from $500. We are keeping the two upgrade triggers from July unchanged and grading them as not met: group adjusted operating margin did not expand year over year (29.4% vs. 29.7%, flat ex pass-through), and Lincare has no resolution. Q4 is the first realistic test of the margin trigger against a soft 29.5% comparison. We add one new condition openly: above roughly $550, or about 28x our FY27 estimate, without a quarter of group margin expansion, the risk/reward would tilt toward Underperform. Below roughly $460, about 24x our FY27 estimate, we would revisit an upgrade on valuation alone. Between those levels the stock is fairly priced for a business compounding at 8–9%.